Thyroid hyperplasia and neoplasm adverse events associated with GLP-1 receptor agonists in FDA Adverse Event Reporting System

Tigran Makunts, Haroutyun Joulfayan, Ruben Abagyan
doi: https://doi.org/10.1101/2023.11.19.23298750

Data Availability

Data Availability Statement The datasets generated and/or analyzed during the current study are available in the FAERS repository, https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html

https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html

Back to top
Posted November 24, 2023.
Download PDF
Data/Code
Email
Thyroid hyperplasia and neoplasm adverse events associated with GLP-1 receptor agonists in FDA Adverse Event Reporting System
Tigran Makunts, Haroutyun Joulfayan, Ruben Abagyan
medRxiv 2023.11.19.23298750; doi: https://doi.org/10.1101/2023.11.19.23298750
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area